Peptide receptor radionuclide therapy (PRRT) with ¹⁷⁷Lubased somatostatin receptor analogues has seen a rapid expansion and has generated significant interest over recent years amongst the nuclear medicine fraternity. In India, this has received a major boost in recent years. The primary impetus for this could be ascribed to two developments as a part of radiopharmaceutical research in the country’s premier atomic energy establishment Bhabha Atomic Research Centre (BARC): (1) the availability of ¹⁷⁷Lu-LuCl₃ at a much lower cost due to indigenous production (less than one-third of commercially available material) and (2) indigenous production of a single-vial kit for the formulation of ^99mTc-HYNIC-TOC, which has played an important role in centres that do not have access to a germanium/gallium generator. Both these developments at the Radiopharmaceutical Division of BARC could be considered major societal contributions to radiopharmaceutical  research in this country in recent years that has benefited a large number of patients with neuroendocrine tumours of various subtypes, both from a diagnostic and a therapeutic standpoint, in multiple clinical centres active in this domain.